Effects of Paclitaxel on CA-125 Serum Levels in Ovarian Cancer Patients
- 31 March 2000
- journal article
- clinical trial
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 76 (3), 326-330
- https://doi.org/10.1006/gyno.1999.5699
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.Journal of Clinical Oncology, 1996
- CA 125 kinetics: A cost-effective clinical tool to evaluate clinical trial outcomes in the 1990sAmerican Journal of Obstetrics and Gynecology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- CA 125 is an unreliable marker for monitoring response to taxol therapy in patients with relapsed ovarian cancerEuropean Journal Of Cancer, 1993
- Serum CA 125 Level Allows Early Identification of Nonresponders during Induction ChemotherapyGynecologic Oncology, 1993
- Modulation of tumour marker CA-125 expression in cultured ovarian carcinoma cellsEuropean Journal Of Cancer, 1992
- Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapyGynecologic Oncology, 1988
- The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapyEuropean Journal of Cancer and Clinical Oncology, 1987
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- Taxol stabilizes microtubules in mouse fibroblast cells.Proceedings of the National Academy of Sciences, 1980